Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $296.9 million as the latest value for Q4 2023.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $296.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $296.9 million, a N/A change, with the full-year FY2023 number at $296.9 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $296.9 million for Q4 2023 at Cartesian Therapeutics, up from $5.0 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $296.9 million in Q4 2023 to a low of $296.9 million in Q4 2023.